| Autor: |
Flicker S; Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Vienna General Hospital, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria. sabine.flicker@meduniwien.ac.at, Gadermaier E, Madritsch C, Valenta R |
| Jazyk: |
angličtina |
| Zdroj: |
Current topics in microbiology and immunology [Curr Top Microbiol Immunol] 2011; Vol. 352, pp. 141-59. |
| DOI: |
10.1007/82_2011_143 |
| Abstrakt: |
The induction of allergen-specific IgG antibodies has been identified as a major mechanism responsible for the reduction of allergic inflammation in allergic patients treated by allergen-specific immunotherapy. Several studies suggest that allergen-specific IgG antibodies induced by vaccination with allergens block mast cell and basophil degranulation, IgE-facilitated allergen presentation to T cells and IgE production. The availability of recombinant allergens and technologies for the production of recombinant human antibodies allows engineering of allergen-specific antibodies which can be used for passive immunization (i.e., therapy) and eventually for the prevention of allergy (i.e., prophylaxis). This chapter summarizes data supporting the possible use of allergen-specific antibodies for treatment and prophylaxis. Finally, concrete approaches for the treatment and prevention of allergy based on blocking antibodies are envisioned. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
